At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 140 enrolled
Drug / intervention
AD036 Dose 1 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
In Brief
A Phase 2 clinical trial evaluating AD036 Dose 1, AD036 Dose 2, and 2 other interventions for Obstructive Sleep Apnea. Completed, enrolled 140 participants across 12 sites.
Detailed Summary
This is a randomized, double blind, placebo-controlled, repeat-dose, parallel arm, outpatient and inpatient phase 2 clinical study to examine the efficacy and safety of three dose levels of AD036 versus placebo in patients with obstructive sleep apnea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Sleep Apnea
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMar 2019
Primary CompletionOct 2019
TodayJul 2026
First PostedFeb 19, 2019
Enrollment StartMar 7, 2019
Primary CompletionOct 23, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.4 years ago
Interventions
AD036 Dose 1drug
AD036 Dose 1 oral capsule administered before sleep
AD036 Dose 2drug
AD036 Dose 2 oral capsule administered before sleep
AD036 Dose 3drug
AD036 Dose 3 oral capsule administered before sleep
Placebodrug
Placebo oral capsule administered before sleep